Rotigotine

Rotigotine

CAT N°: 20246
Price:

From 48.00 40.80

Rotigotine is a non-selective dopamine receptor agonist with pEC50 values of 9.6, 10.4, 8.2, 7.7, and 7.7 for D1, D2, D3, D4, and D5, respectively.{32322} It demonstrates a high-affinity for D1, D2, and D3 with lesser affinity for D4 and D5 receptor subtypes.{32322} This binding profile is similar to that of apomorphine (Item No. 16094) and pergolide but differentiated from that of pramipexole (Item No. 11981) and ropinirole, which have a more narrow profile of receptor specificity.{32322} Each of these agonists demonstrates anti-Parkinsonian effects in animal and clinical models through their ability to directly activate dopamine receptors.{32322}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (6S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol
  • Correlated keywords
    • dopamine receptor apomorphine pergolide pramipexole ropinirole SPM962 neupro N0427 N0923 neupro (S)-(-)-rotigotine N-0427 antiparkinsonian
  • Product Overview:
    Rotigotine is a non-selective dopamine receptor agonist with pEC50 values of 9.6, 10.4, 8.2, 7.7, and 7.7 for D1, D2, D3, D4, and D5, respectively.{32322} It demonstrates a high-affinity for D1, D2, and D3 with lesser affinity for D4 and D5 receptor subtypes.{32322} This binding profile is similar to that of apomorphine (Item No. 16094) and pergolide but differentiated from that of pramipexole (Item No. 11981) and ropinirole, which have a more narrow profile of receptor specificity.{32322} Each of these agonists demonstrates anti-Parkinsonian effects in animal and clinical models through their ability to directly activate dopamine receptors.{32322}

We also advise you